Celgene nails down a 'transformational' $7.2B Receptos buyout; Lilly, Boehringer roll out Lantus in first big market;

@FierceBiotech: UPDATED: Amgen gets a big win with FDA OK for PCSK9 cholesterol drug. Article | Follow @FierceBiotech

@JohnCFierce: Eli Lilly's marginal cancer drug becomes Exhibit A in pricing dilemma. Report | Follow @JohnCFierce

> Celgene ($CELG) has closed on its $7.2 billion buyout of Receptos. "The Receptos acquisition provides a transformational opportunity for Celgene to impact multiple therapeutic areas," said Celgene CEO Bob Hugin. "This acquisition enhances our I&I portfolio and allows us to leverage the investments made in our global organization to accelerate our growth in the medium and long-term." Release

> Eli Lilly ($LLY) and Boehringer Ingelheim have rolled out their biosimilar version of Lantus in its first major market. The U.K. launch follows some smaller rollouts in Eastern Europe--and it's the next move in a planned worldwide assault on the Sanofi ($SNY) diabetes stalwart. Story

Medical Device News

@FierceMedDev: FDA scolds Cepheid for manufacturing issues in Sweden. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Updated $ABT's interest in $STJ w/ info from old article on their prior partnership. Neat to add context from 2012. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: J&J and PCH launch hardware startup accelerator. Story | Follow @EmilyWFierce

> Nerve repair micro-cap AxoGen nabs $17.5M from PE group to get to cash-flow positive. More

> Recall roundup: CareFusion infusion pump, J&J sedation device, Teleflex endobronchial tube. Story

> DOD chips in for $171M Silicon Valley flexible electronics project. Article

Pharma News

@FiercePharma: Patterson shares fall on missed sales and earnings targets. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: ICYMI: North Carolina wins Novo prize--$1.2B plant, 700 jobs as Novo builds first US, API plant. Article | Follow @EricPFierce

@CarlyHFierce: Can Sprout's Addyi shrug off serious side effects? These blockbusters did. FiercePharmaMarketing story | Follow @CarlyHFierce

> Celgene nails down $7.2B takeover of Receptos. Item

> J&J brings 500 jobs to Florida with new shared services HQ. More

> Mylan shareholders favor Perrigo takeover. Story

> Sweden's Meda weighs $1B sale of its U.S. business. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.